Printer Friendly

CLINICAL TRIALS OF IMMUNOGEN'S ONCOLYSIN B EXPANDED; NCI TO BEGIN MULTICENTER STUDY IN CHILDREN WITH LEUKEMIA AND LYMPHOMA

CLINICAL TRIALS OF IMMUNOGEN'S ONCOLYSIN B EXPANDED; NCI TO BEGIN
 MULTICENTER STUDY IN CHILDREN WITH LEUKEMIA AND LYMPHOMA
 CAMBRIDGE, Mass., March 30 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the start of a multicenter Phase I/II clinical trial of Oncolysin(R) B in the treatment of children with B- lineage acute lymphoblastic leukemia (ALL) or lymphoma. The trial, at 13 centers across the United States, is being conducted by the Children's Cancer Study Group (CCSG) under an Investigational New Drug application (IND) filed by the National Cancer Institute (NCI).
 Children who have relapsed following prior therapy will be eligible for the trial. "ALL is the most common type of childhood leukemia," notes Patricia Dinndorf, M.D., of Children's National Medical Center, Washington, D.C., and chairperson of the CCSG Study Committee which is overseeing the trial. "Although most children with ALL have a very good chance of being cured with current therapy, there remains a group of children who relapse and, ultimately, die of their disease. Because Oncolysin B may provide a novel approach to the treatment of this common childhood malignancy, CCSG is anxious to evaluate this drug, and hopefully add it to our armamentarium in the battle against childhood cancer."
 "We are pleased that the National Cancer Institute is sponsoring this effort," states Mitchel Sayare, ImmunoGen president and CEO. "This is the second clinical trial of Oncolysin B conducted under an NCI IND." Last year, NCI began a clinical trial of Oncolysin B in patients with AIDS-related lymphoma. Sayare adds that, "We have initiated extensive clinical studies with Oncolysin B in various settings involving B-cell leukemias and lymphomas -- including ImmunoGen's own ongoing pediatric trial. They are yielding new and valuable information on how best to treat these diseases."
 Oncolysin B is comprised of a highly specific monoclonal antibody linked to "blocked ricin," the company's proprietary form of the powerful plant toxin, ricin. ImmunoGen's technology for blocking the ricin molecule prevents the indiscriminate binding of ricin to all cells, while maintaining the potency of whole ricin. Oncolysin B is currently in multicenter Phase II trials in the treatment of B-cell leukemias and lymphoma, multiple myeloma and as a purging agent in autologus bone marrow trnasplant.
 ImmunoGen, Inc. is a Cambridge, Mass.-based biotechnology company that develops biopharmaceuticals, primarily for the treatment of cancer. The company produces proprietary toxins, drugs and biologicals conjugated to highly specific monoclonal antibodies which search out and destroy cancer cells. ImmunoGen currently has three Oncolysin products in human clinical trials and has filed with the U.S. Food and Drug Administration to begin clincial testing of its fourth product.
 -0- 3/30/92
 /CONTACT: Mark Ratner of ImmunoGen, 617-661-9312/
 (IMGN) CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PDT


DD -- NE002 -- 2702 03/30/92 08:37 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:464
Previous Article:CHUBB UNIT SETTLES INSURANCE COVERAGE LITIGATION
Next Article:HELIAN INCREASES EARNINGS 67 PERCENT ON RECORD FIRST QUARTER REVENUES
Topics:


Related Articles
IMMUNOGEN'S BLOCKED RICIN TECHNOLOGY INCREASES POTENCY OF CANCER THERAPEUTICS 1,000-FOLD: RESEARCHERS REPORT DATA IN CANCER RESEARCH
IMMUNOGEN'S BLOCKED RICIN TECHNOLOGY INCREASES POTENCY OF CANCER THERAPEUTICS 1,000-FOLD: RESEARCHERS REPORT DATA IN CANCER RESEARCH
IMMUNOGEN'S PHASE I CLINICAL TRIALS DATA WITH ONCOLYSIN B PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY MEETING
IMMUNOGEN ANNOUNCES SECOND QUARTER FISCAL YEAR 1992 RESULTS
IMMUNOGEN ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 1992 RESULTS
RESULTS OF IMMUNOGEN'S PHASE I CLINICAL TRIAL USING ONCOLYSIN B SUBSEQUENT TO BONE MARROW TRANSPLANTATION PUBLISHED IN BLOOD
ONCOLYSIN(R) CD6, IMMUNOGEN'S FOURTH PRODUCT, ENTERS PHASE I HUMAN CLINICAL TRIALS
IMMUNOGEN OPENS A NEW MANUFACTURING FACILITY IN CANTON, MASSACHUSETTS
IMMUNOGEN RECEIVES U.S. PATENT ON USE OF ITS CYTOTOXIC AGENT, DC1, IN IMMUNOCONJUGATES
Cytokinetics Announces Clinical Trial Data with Ispinesib and Non-Clinical Data with SB-743921 to be Presented at the 2006 EORTC-NCI-AACR...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters